Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LCDD
MCID: LGH004
MIFTS: 44

Light Chain Deposition Disease (LCDD) malady

Categories: Rare diseases, Nephrological diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Light Chain Deposition Disease

About this section

Aliases & Descriptions for Light Chain Deposition Disease:

Name: Light Chain Deposition Disease 50 56
Light-Chain Deposition Disease 50
Light Chain Disease 69
Lcdd 56

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 56  
Rare renal diseases
Rare haematological diseases


External Ids:

Orphanet 56 ORPHA93558
ICD10 via Orphanet 34 D89.8
Sources

Summaries for Light Chain Deposition Disease

About this section
NIH Rare Diseases : 50 light chain deposition disease (lcdd) is a rare condition characterized by the deposition of specific proteins (monoclonal light chains) in the kidneys and other organs. light chains are used to make antibodies that the body needs to fight infection. people with lcdd make too many light chains, which get deposited in many body tissues. while lcdd can occur in any organ, the kidneys are always involved. signs and symptoms of lcdd may include protein in the urine; decreased kidney function; and/or nephrotic syndrome. rarely, a person with lcdd may have symptoms from cardiac (heart) or liver involvement. the underlying cause of lcdd is unknown. it is often associated with multiple myeloma. lcdd may progress to multiple myeloma, or it may be present with multiple myeloma when it is first diagnosed. the goal of treating lcdd is to slow the production of light chains and their damage to organs. treatment may include chemotherapy with a drug called bortezomib; autologous stem cell transplantation; immunomodulatory drugs; and/or kidney transplant. if untreated, end-stage renal disease occurs in 70% of cases. last updated: 8/2/2016

MalaCards based summary : Light Chain Deposition Disease, also known as light-chain deposition disease, is related to histiocytosis and lacrimal duct defect. An important gene associated with Light Chain Deposition Disease is MMP7 (Matrix Metallopeptidase 7), and among its related pathways/superpathways are Integrin Pathway and Degradation of the extracellular matrix. The drugs Dexamethasone and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and heart, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 71 Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition... more...

Sources

Related Diseases for Light Chain Deposition Disease

About this section

Diseases related to Light Chain Deposition Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Related Disease Score Top Affiliating Genes
1 histiocytosis 29.6 MMP1 MMP2 MMP9
2 lacrimal duct defect 11.4
3 amyloidosis 10.3
4 neuropathy, hereditary sensory, type id 10.3 MMP14 MMP2
5 anisomastia 10.3 MMP14 MMP2
6 facio skeletal genital syndrome rippberger type 10.3 MMP2 MMP9
7 leukoencephalopathy palmoplantar keratoderma 10.3 MMP2 MMP9
8 thymus adenocarcinoma 10.3 MMP2 MMP9
9 spinal meninges cancer 10.3 MMP2 MMP9
10 neonatal hypoxic and ischemic brain injury 10.2 MMP2 MMP9
11 brain meningioma 10.2 MMP7 MMP9
12 benign focal seizures of adolescence 10.2 MMP12 MMP7
13 viral meningitis 10.2 MMP2 MMP9
14 lymphocytic colitis 10.2 MMP2 MMP9
15 penis agenesis 10.2 MMP7 MMP9
16 chondrodysplasia punctata, rhizomelic, type 1 10.2 MMP7 MMP9
17 multiple myeloma 10.2
18 appendix carcinoid tumor 10.2 MMP2 MMP9
19 corneal staphyloma 10.2 MMP2 MMP9
20 optic atrophy 2 10.2 MMP7 TNC
21 schwannomatosis 10.2 MMP2 MMP9
22 retinal artery occlusion 10.2 MMP2 MMP9
23 acute tricyclic antidepressant poisoning 10.2 MMP2 MMP7 MMP9
24 bulbomembranous urethral cancer 10.2 MMP2 MMP9
25 tinea profunda 10.2 MMP2 MMP7 MMP9
26 retinal drusen 10.2 MMP2 MMP7 MMP9
27 lower lip cancer 10.2 MMP2 MMP7 MMP9
28 adenocarcinoma in situ 10.2 MMP14 MMP2 MMP9
29 noonan syndrome 4 10.2 MMP1 MMP2
30 breast papillary carcinoma 10.2 MMP2 MMP9
31 proctitis 10.1 MMP2 MMP7 MMP9
32 polyp of corpus uteri 10.1 MMP1 MMP2
33 parametrium malignant neoplasm 10.1 MMP14 MMP2 MMP9
34 autoimmune polyendocrine syndrome type 1 10.1 MMP9 TNC
35 adult-onset distal myopathy due to vcp mutation 10.1 MMP1 MMP9
36 juvenile astrocytoma 10.1 ACTC1 MMP2 MMP9
37 diffuse large b-cell lymphoma 10.1 MMP1 MMP9
38 angiomyoma 10.1 MMP1 MMP2
39 cavernous malformation 10.1 MMP12 MMP2 MMP9
40 ectropion 10.1 MMP1 MMP9
41 hypogonadotropic hypogonadism 20 with or without anosmia 10.1 MMP14 MMP2 MMP9
42 mitochondrial encephalomyopathy 10.1 MMP14 MMP2 TNC
43 maxillary neoplasm 10.1 MMP2 MMP9 TNC
44 chiasmal syndrome 10.1 ACTC1 CD68
45 adenoid squamous cell carcinoma 10.1 MMP2 MMP9
46 subglottis neoplasm 10.1 MMP1 MMP14 MMP2
47 hemangioma of liver 10.1 ACTC1 CD68
48 spinocerebellar ataxia, autosomal recessive 2 10.0 MMP1 MMP14 MMP2
49 cystic lymphangioma 10.0 MMP1 MMP7 MMP9
50 adult neuronal ceroid lipofuscinosis 10.0 MMP1 MMP2 MMP9

Graphical network of the top 20 diseases related to Light Chain Deposition Disease:



Diseases related to Light Chain Deposition Disease
Sources

Symptoms & Phenotypes for Light Chain Deposition Disease

About this section

MGI Mouse Phenotypes related to Light Chain Deposition Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.56 MMP9 TNC ACTC1 MMP1 MMP12 MMP14
2 immune system MP:0005387 9.17 CD68 MMP1 MMP12 MMP14 MMP2 MMP7
Sources

Drugs & Therapeutics for Light Chain Deposition Disease

About this section

Drugs for Light Chain Deposition Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
2
Melphalan Approved Phase 3,Phase 1,Phase 2 148-82-3 4053 460612
3
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
4
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
5
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
6 Dexamethasone acetate Phase 3,Phase 1,Phase 2 1177-87-3
7 Alkylating Agents Phase 3,Phase 1,Phase 2
8 glucocorticoids Phase 3,Phase 1,Phase 2
9
protease inhibitors Phase 3,Phase 1,Phase 2
10 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
11 HIV Protease Inhibitors Phase 3,Phase 1,Phase 2
12 Hormone Antagonists Phase 3,Phase 1,Phase 2
13 Dexamethasone 21-phosphate Phase 3,Phase 1,Phase 2
14 Hormones Phase 3,Phase 1,Phase 2
15 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
16 Angiogenesis Inhibitors Phase 3,Phase 1,Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
18 Angiogenesis Modulating Agents Phase 3,Phase 1,Phase 2
19 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
20 Immunoglobulin G Phase 3,Phase 2
21 Immunoglobulins Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 3,Phase 1,Phase 2
23 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
25 Antiemetics Phase 3,Phase 1,Phase 2
26 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
27 Antibodies Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2
29 BB 1101 Phase 3,Phase 1,Phase 2
30 Autonomic Agents Phase 3,Phase 1,Phase 2
31 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
32 phenylalanine Nutraceutical Phase 3,Phase 2
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
35
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
36
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
37
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
Etoposide Approved Phase 2 33419-42-0 36462
40
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
41
Lenograstim Approved Phase 2 135968-09-1
42
Doxil Approved June 1999 Phase 2 31703
43 Mitogens Phase 2
44 Albumin-Bound Paclitaxel Phase 2
45 Topoisomerase Inhibitors Phase 2
46 Endothelial Growth Factors Phase 2
47 Antimalarials Phase 2
48 Antibiotics, Antitubercular Phase 2
49 Antimitotic Agents Phase 2
50 Antirheumatic Agents Phase 2

Interventional clinical trials:

(show all 20)
id Name Status NCT ID Phase
1 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3
2 Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis Completed NCT00344526 Phase 3
3 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Recruiting NCT01169337 Phase 3
4 The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis Active, not recruiting NCT02312206 Phase 3
5 Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis Completed NCT00621400 Phase 1, Phase 2
6 Safety and Effect of Doxycycline in Patients With Amyloidosis Completed NCT01677286 Phase 2
7 Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis Completed NCT00607581 Phase 2
8 Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Completed NCT00861705 Phase 2
9 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Recruiting NCT01849783 Phase 2
10 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Active, not recruiting NCT00520767 Phase 2
11 Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis Not yet recruiting NCT03130348 Phase 2
12 HD Melphalan and SCT in Patients With IGDD or LCDD Terminated NCT00681044 Phase 2
13 Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT01533194 Phase 1
14 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1
15 Radioimmunoimaging of Light Chain (AL) Amyloidosis Completed NCT01815086 Phase 1
16 First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Suspended NCT01728259 Phase 1
17 Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis Recruiting NCT02338427
18 Molecular Imaging of Primary Amyloid Cardiomyopathy Recruiting NCT02641145
19 Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis Active, not recruiting NCT01383759
20 Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects Terminated NCT01018927

Search NIH Clinical Center for Light Chain Deposition Disease

Sources

Genetic Tests for Light Chain Deposition Disease

About this section
Sources

Anatomical Context for Light Chain Deposition Disease

About this section

MalaCards organs/tissues related to Light Chain Deposition Disease:

39
Kidney, Liver, Heart, Lung, B Cells, Brain, Spleen
Sources

Publications for Light Chain Deposition Disease

About this section

Articles related to Light Chain Deposition Disease:

(show top 50) (show all 165)
id Title Authors Year
1
Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions. ( 28050001 )
2017
2
Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach. ( 27101986 )
2016
3
OCULAR MANIFESTATIONS OF MONOCLONAL IMMUNOGLOBULIN LIGHT CHAIN DEPOSITION DISEASE. ( 27315323 )
2016
4
Nodular pulmonary light chain deposition disease: an entity associated with SjAPgren syndrome or marginal zone lymphoma. ( 26502747 )
2016
5
Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone. ( 27181540 )
2016
6
Nodular pulmonary light chain deposition disease. ( 27306574 )
2016
7
Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone. ( 28001187 )
2016
8
A case of light chain deposition disease in kidney in a known case of multiple myeloma. ( 27728501 )
2016
9
Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis. ( 26794829 )
2016
10
Spontaneous splenic rupture in a patient with light-chain deposition disease undergoing autologous peripheral blood stem cell transplantation. ( 27384856 )
2016
11
Unusual case of light chain deposition disease kappa restricted in a case of multiple myeloma. ( 27728483 )
2016
12
A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. ( 26988342 )
2016
13
ATYPICAL MACULOPATHY IN A PATIENT WITH LIGHT CHAIN DEPOSITION DISEASE MIMICKING ADVANCED GEOGRAPHIC ATROPHY. ( 26934302 )
2016
14
Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease. ( 27211983 )
2016
15
Intracystic hemorrhage in a patient with pulmonary cystic disorder related to light-chain deposition disease. ( 27756655 )
2016
16
Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease. ( 27746438 )
2016
17
Unusual Presentation of Light Chain Deposition Disease: A Case Report. ( 27437235 )
2016
18
Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center. ( 27056200 )
2016
19
Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male. ( 28083151 )
2016
20
Light Chain Deposition Disease After Kidney Transplantation With Long Graft Survival: Case Report. ( 26915878 )
2016
21
Bortezomib Based Chemotherapy for Light Chain Deposition Disease. ( 27762125 )
2016
22
Natural history and outcome of light chain deposition disease. ( 26392598 )
2015
23
Enlightening light chain deposition disease. ( 26705338 )
2015
24
Pulmonary light-chain deposition disease: CT and pathology findings in nine patients. ( 25659938 )
2015
25
ENHANCED DEPTH IMAGING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FEATURES OF LIGHT CHAIN DEPOSITION DISEASE. ( 26398301 )
2015
26
AJKD Atlas of Renal Pathology: Light Chain Deposition Disease. ( 26593321 )
2015
27
Blood stem cell transplantation to treat cystic lung light chain deposition disease. ( 26160867 )
2015
28
Light-Chain Deposition Disease Successfully Treated with Bortezomib in an Elderly Patient: A Case Report and Review of the Literature. ( 26568005 )
2015
29
Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both. ( 25860232 )
2015
30
Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge. ( 25441103 )
2015
31
Nonamyloid tumoral light-chain-deposition disease (aggregoma) of the paraspinal region. ( 26253133 )
2015
32
Isolated intracerebral light chain deposition disease: novel imaging and pathologic findings. ( 25084689 )
2014
33
Light chain deposition disease and proximal tubulopathy in two successive kidney allografts. ( 25492671 )
2014
34
Hypertension, renal failure, and edema in a 38-year-old man: light chain deposition disease; a case report and review of the literature. ( 24772399 )
2014
35
Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. ( 24619059 )
2014
36
Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report. ( 25249814 )
2014
37
Osteolytic femoral lesion detected by sonography in a case of light chain deposition disease. ( 24449208 )
2014
38
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach? ( 25022598 )
2014
39
Education and imaging. Hepatobiliary and Pancreatic: Portal hypertension due to hepatic light chain deposition disease. ( 24832781 )
2014
40
Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease. ( 22504167 )
2013
41
Retinal haemorrhage, subretinal pigment epithelial deposits and serous macular detachment in light chain deposition disease. ( 23853165 )
2013
42
Serous retinal detachments associated with light chain deposition disease. ( 25391113 )
2013
43
Light chain deposition disease; there are reasons for confusion. ( 25340150 )
2013
44
Retinal pigment epithelial detachments and tears, and progressive retinal degeneration in light chain deposition disease. ( 23385633 )
2013
45
Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and "aggregoma": an update on classification and diagnosis. ( 23947787 )
2013
46
Portal hypertension related to light chain deposition disease of liver: an enlightening experience. ( 23723105 )
2013
47
Mass spectrometry-based proteomic analysis: a good diagnostic tool for cystic lung light chain deposition disease. ( 23905535 )
2013
48
Light chain deposition disease: novel biological insights and treatment advances. ( 22471811 )
2012
49
Cast nephropathy and light-chain deposition disease in WaldenstrAPm macroglobulinemia. ( 22721930 )
2012
50
A case of recurrent light chain deposition disease after living-related renal transplantation - detailed process of the recurrence. ( 22747479 )
2012
Sources

Variations for Light Chain Deposition Disease

About this section
Sources

Expression for Light Chain Deposition Disease

About this section
Search GEO for disease gene expression data for Light Chain Deposition Disease.
Sources

Pathways for Light Chain Deposition Disease

About this section

Pathways related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Integrin Pathway 60
Show member pathways
 13.15 MMP1 MMP12 MMP2 MMP7 MMP9 TNC
2
Degradation of the extracellular matrix 62
Show member pathways
 12.46 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3
TGF-beta Signaling Pathway (WikiPathways) 1
11.85 MMP1 MMP12 TNC
4
Colorectal Cancer Metastasis 60
11.85 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
5
Interleukin-4 and 13 signaling 62
11.76 MMP1 MMP2 MMP9
6
Adhesion 4
11.73 MMP14 MMP2 MMP9
7
Angiogenesis (CST) 4
11.61 MMP2 MMP7 MMP9 TNC
8
Bladder cancer 1 37
11.53 MMP1 MMP2 MMP9
9
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 MMP1 MMP2 MMP9
10
AGE/RAGE pathway 1
11.44 MMP14 MMP2 MMP7 MMP9
11
Matrix Metalloproteinases 1
Show member pathways
 11.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
12
Cell adhesion_Cell-matrix glycoconjugates 21
11.22 MMP1 MMP9 TNC
13
A-beta Pathways: Uptake and Degradation 61
11.14 MMP2 MMP9
14
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.14 MMP1 MMP2 MMP9
15
Syndecan-4-mediated signaling events 1
11.08 MMP9 TNC
16
A-beta Pathways: Plaque Formation and APP Metabolism 61
10.99 MMP2 MMP9
17
Plasma membrane estrogen receptor signaling 1
10.98 MMP2 MMP9
18
Cell adhesion_ECM remodeling 21
10.89 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
19
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 62
10.88 MMP1 MMP2
20
Syndecan-1-mediated signaling events 1
10.81 MMP1 MMP7 MMP9
Sources

GO Terms for Light Chain Deposition Disease

About this section

Cellular components related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 IGKC IGKV1-5 MMP1 MMP12 MMP2 MMP7
2 extracellular space GO:0005615 9.76 ACTC1 IGKC MMP12 MMP14 MMP2 MMP7
3 blood microparticle GO:0072562 9.5 ACTC1 IGKC IGKV1-5
4 proteinaceous extracellular matrix GO:0005578 9.43 MMP1 MMP12 MMP2 MMP7 MMP9 TNC
5 extracellular matrix GO:0031012 9.17 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Biological processes related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.76 IGKC IGKV1-5 MMP1 MMP12 MMP14 MMP2
2 leukocyte migration GO:0050900 9.62 IGKC IGKV1-5 MMP1 MMP9
3 cellular protein metabolic process GO:0044267 9.58 MMP1 MMP2 TNC
4 endodermal cell differentiation GO:0035987 9.43 MMP14 MMP2 MMP9
5 extracellular matrix disassembly GO:0022617 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.37 MMP2 MMP9
7 collagen catabolic process GO:0030574 9.1 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Molecular functions related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.88 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
2 zinc ion binding GO:0008270 9.8 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3 peptidase activity GO:0008233 9.73 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
4 metallopeptidase activity GO:0008237 9.63 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
5 endopeptidase activity GO:0004175 9.54 MMP1 MMP12 MMP9
6 metalloendopeptidase activity GO:0004222 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
7 serine-type endopeptidase activity GO:0004252 9.23 IGKC IGKV1-5 MMP1 MMP12 MMP14 MMP2
Sources

Sources for Light Chain Deposition Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....